Clinical Trial Update: Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating daratumumab with ixazomib and dexamethasone in relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• ixazomib (ixazomib)

Snippet

Sponsor: Hellenic Society of Hematology | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN